NASDAQ · IMTX
Healthcare · Biotechnology
$9.09
Down-$0.16 (-1.73%)
Updated Aug 19, 2026, 9:16 AM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
IMTX closed at $9.09 after 21 trading sessions, down 3.40% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 18, 2026 | $9.06 | $9.29 | $8.83 | $9.09 | 995.02K |
| Aug 17, 2026 | $9.37 | $9.56 | $9.20 | $9.25 | 1.07M |
| Aug 14, 2026 | $9.68 | $9.68 | $9.39 | $9.44 | 362.69K |
| Aug 13, 2026 | $9.71 | $9.98 | $9.535 | $9.59 | 284.2K |
| Aug 12, 2026 | $9.79 | $9.91 | $9.59 | $9.71 | 188.42K |
| Aug 11, 2026 | $9.76 | $9.86 | $9.52 | $9.75 | 264.41K |
| Aug 10, 2026 | $9.66 | $9.86 | $9.60 | $9.72 | 240.64K |
| Aug 7, 2026 | $9.56 | $9.91 | $9.475 | $9.65 | 309.3K |
| Aug 6, 2026 | $9.86 | $9.8711 | $9.38 | $9.42 | 320.96K |
| Aug 5, 2026 | $9.40 | $9.79 | $9.16 | $9.77 | 676.49K |
| Aug 4, 2026 | $9.08 | $9.415 | $9.045 | $9.38 | 442.27K |
| Aug 3, 2026 | $8.62 | $9.055 | $8.37 | $9.02 | 257.48K |
| Jul 31, 2026 | $9.20 | $9.20 | $8.575 | $8.66 | 213.1K |
| Jul 30, 2026 | $9.05 | $9.57 | $8.915 | $9.20 | 1.61M |
| Jul 29, 2026 | $8.68 | $9.11 | $8.51 | $8.99 | 433.92K |
| Jul 28, 2026 | $8.56 | $8.75 | $8.17 | $8.735 | 535.04K |
| Jul 27, 2026 | $9.19 | $9.45 | $8.61 | $8.63 | 453.19K |
| Jul 24, 2026 | $9.32 | $9.32 | $9.01 | $9.08 | 290.49K |
| Jul 23, 2026 | $9.02 | $9.4075 | $9.00 | $9.29 | 352.46K |
| Jul 22, 2026 | $9.265 | $9.50 | $9.07 | $9.17 | 249.73K |
| Jul 21, 2026 | $9.23 | $9.475 | $9.22 | $9.41 | 157.47K |
The latest Smart Investors Daily articles mentioning IMTX.
IMTX research
Company profile and research snapshot.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 19, 2026 | Chardan Capital | Buy | — |
| Apr 28, 2026 | TD Cowen | Buy | — |
| Nov 24, 2025 | Chardan Capital | Buy | — |
| Nov 19, 2025 | Mizuho | Outperform | — |
| Nov 18, 2025 | Guggenheim | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 18, 2026
Immatics (NASDAQ:IMTX) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.43) by 23.26 percent. This is a 19.7 percent increase over losses of $(0.66) per share from the
SeekingAlpha · Jun 16, 2026
Immatics is evolving into a PRAME-focused oncology platform with three monetization paths. Read why I am bullish on IMTX stock.
Benzinga · Mar 5, 2026
Benzinga · Mar 5, 2026
Immatics (NASDAQ:IMTX) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.48) by 29.17 percent. This is a 170.83 percent decrease over earnings of $0.48 per share from the
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning IMTX.
